Ultrasonically controlled albumin-conjugated liposomes for breast cancer therapy
Targeted liposomes have high potentials in the specific and effective delivery of their loaded therapeutic agents to the tumour site. Once at the tumour site, it is important that these liposomes are triggered to release their load in a controlled and effective manner. In this study, pegylated (stea...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-12-01
|
| Series: | Artificial Cells, Nanomedicine, and Biotechnology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21691401.2019.1573175 |
| _version_ | 1818008715359420416 |
|---|---|
| author | Nahid S. Awad Vinod Paul Mohammad H. Al-Sayah Ghaleb A. Husseini |
| author_facet | Nahid S. Awad Vinod Paul Mohammad H. Al-Sayah Ghaleb A. Husseini |
| author_sort | Nahid S. Awad |
| collection | DOAJ |
| description | Targeted liposomes have high potentials in the specific and effective delivery of their loaded therapeutic agents to the tumour site. Once at the tumour site, it is important that these liposomes are triggered to release their load in a controlled and effective manner. In this study, pegylated (stealth) liposomes conjugated to human serum albumin (HSA) were investigated for the delivery of a model drug (calcein) to breast cancer cells. The fluorescent results showed that calcein uptake by the two breast cancer cell lines (MDA-MB-231 and MCF-7) was significantly higher with the HSA-PEG liposomes compared to the non-targeted control liposomes. Furthermore, the exposure to low-frequency ultrasound (LFUS) resulted in a statistically significant uptake of calcein compared to the uptake without ultrasound. The described drug delivery (DD) system, which involves combining the targeted liposomal formulation with ultrasonic triggering techniques, promises a safe, effective and site-specific breast cancer therapy. |
| first_indexed | 2024-04-14T05:32:55Z |
| format | Article |
| id | doaj.art-7f14952a5aff4649a39d22a3b8d31c26 |
| institution | Directory Open Access Journal |
| issn | 2169-1401 2169-141X |
| language | English |
| last_indexed | 2024-04-14T05:32:55Z |
| publishDate | 2019-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Artificial Cells, Nanomedicine, and Biotechnology |
| spelling | doaj.art-7f14952a5aff4649a39d22a3b8d31c262022-12-22T02:09:44ZengTaylor & Francis GroupArtificial Cells, Nanomedicine, and Biotechnology2169-14012169-141X2019-12-0147170571410.1080/21691401.2019.1573175Ultrasonically controlled albumin-conjugated liposomes for breast cancer therapyNahid S. Awad0Vinod Paul1Mohammad H. Al-Sayah2Ghaleb A. Husseini3Department of Chemical Engineering, American University of Sharjah, Sharjah, UAEDepartment of Chemical Engineering, American University of Sharjah, Sharjah, UAEDepartment of Biology, Chemistry and Environmental Sciences, American University of Sharjah, Sharjah, UAEDepartment of Chemical Engineering, American University of Sharjah, Sharjah, UAETargeted liposomes have high potentials in the specific and effective delivery of their loaded therapeutic agents to the tumour site. Once at the tumour site, it is important that these liposomes are triggered to release their load in a controlled and effective manner. In this study, pegylated (stealth) liposomes conjugated to human serum albumin (HSA) were investigated for the delivery of a model drug (calcein) to breast cancer cells. The fluorescent results showed that calcein uptake by the two breast cancer cell lines (MDA-MB-231 and MCF-7) was significantly higher with the HSA-PEG liposomes compared to the non-targeted control liposomes. Furthermore, the exposure to low-frequency ultrasound (LFUS) resulted in a statistically significant uptake of calcein compared to the uptake without ultrasound. The described drug delivery (DD) system, which involves combining the targeted liposomal formulation with ultrasonic triggering techniques, promises a safe, effective and site-specific breast cancer therapy.https://www.tandfonline.com/doi/10.1080/21691401.2019.1573175Human serum albuminliposomescalceinbreast cancerultrasound |
| spellingShingle | Nahid S. Awad Vinod Paul Mohammad H. Al-Sayah Ghaleb A. Husseini Ultrasonically controlled albumin-conjugated liposomes for breast cancer therapy Artificial Cells, Nanomedicine, and Biotechnology Human serum albumin liposomes calcein breast cancer ultrasound |
| title | Ultrasonically controlled albumin-conjugated liposomes for breast cancer therapy |
| title_full | Ultrasonically controlled albumin-conjugated liposomes for breast cancer therapy |
| title_fullStr | Ultrasonically controlled albumin-conjugated liposomes for breast cancer therapy |
| title_full_unstemmed | Ultrasonically controlled albumin-conjugated liposomes for breast cancer therapy |
| title_short | Ultrasonically controlled albumin-conjugated liposomes for breast cancer therapy |
| title_sort | ultrasonically controlled albumin conjugated liposomes for breast cancer therapy |
| topic | Human serum albumin liposomes calcein breast cancer ultrasound |
| url | https://www.tandfonline.com/doi/10.1080/21691401.2019.1573175 |
| work_keys_str_mv | AT nahidsawad ultrasonicallycontrolledalbuminconjugatedliposomesforbreastcancertherapy AT vinodpaul ultrasonicallycontrolledalbuminconjugatedliposomesforbreastcancertherapy AT mohammadhalsayah ultrasonicallycontrolledalbuminconjugatedliposomesforbreastcancertherapy AT ghalebahusseini ultrasonicallycontrolledalbuminconjugatedliposomesforbreastcancertherapy |